FRMD6 antibody | knockout validation | Cell Signaling 14688

This is a knockout-validated antibody summary, based on the publication "In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

FRMD6 antibody | knockout validation | Cell Signaling 14688 figure 1
Figure 1. The effects of SAV1 and FRMD6 knockouts on SAV1 and FRMD6 expression as well as YAP phosphorylation and total protein levels in SUM159 cells were assessed by immunoblotting with the indicated antibodies. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: FRMD6

Catalog number: 14688

Summary: Rabbit monoclonal antibody against a synthetic peptide corresponding to residues surrounding Phe608 of human FRMD6 protein. Reacts with human, mouse, and rat. It is predicted to react based on 100% sequence homology with bovine, dog, and pig. Suitable for western blot and immunoprecipitation.

Validation Method

Western blot

Sample

Control and FRMD6 knockout SUM159 cells.

Blocking agent

5% non-fat dry milk for 1h at room temperature.

Primary incubation

1:1,000 dilution overnight at 4°C

Secondary incubation

Specific secondary antibodies for 1h.

Detection
References
  1. Dai M, Yan G, Wang N, Daliah G, Edick A, Poulet S, et al. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy. Nat Commun. 2021;12:3055 pubmed publisher